ABSTRACT-Introduction: Muscle wasting (MW) in catabolic conditions (e.g., burn injury [BI]) is a major risk factor affecting prognosis. Activation of interleukin-1b (IL-1b)/nuclear factor-kappa B (NF-kB), interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3), and/or forkhead box O transcriptional factor (FOXO)-mediated gene transcription pathways is the pivotal trigger of inflammatory response-induced protein catabolic processes in muscle. The a7 acetylcholine receptors (a7AChRs) are upregulated in macrophages and peripheral tissues including skeletal muscle during MW conditions. Stimulation of a7AChRs mitigates inflammatory responses. Hypothesis tested is that attenuation of inflammation by a7AChR stimulation with specific a7AChR agonist, GTS-21, will reverse BI-induced body mass and MW by modulating inflammatory and proteolytic signals. Methods: Body surface area (30%) BI or sham BI mice were treated with GTS-21 or saline. Tibialis anterior (TA) muscle was harvested at 6 h, day 1 or 3 to examine inflammatory and proteolytic signals. Results: GTS-21 significantly ameliorated the BI-induced increased expression of inflammatory cytokines IL-6, IL-1b, C-X-C motif chemokine ligand 2 (6 h), phosphorylated STAT3, and NF-kB (day 1) in TA muscle. GTS-21 also significantly inhibited BI-induced increase of MuRF1 and FOXO1 (day 1). Consistent with the cytokine and inflammatory mediator changes, BI-induced body weight and TA muscle mass loss at day 3 were mitigated by GTS-21 treatment. The beneficial effect of GTS-21 on BI changes was absent in methyllycaconitine (a7AChR antagonist)-treated wild-type and a7AChR knockout mice. Conclusion: GTS-21 stimulation of a7AChRs, by modulating multiple molecular signals related to inflammation and proteolysis, attenuates protein wasting, evidenced by maintenance of body weight and attenuation of distant muscle mass loss after BI. GTS-21 can be a novel, potent therapeutic option for reversal of BI-induced MW.
INTRODUCTION
Muscle wasting (MW) is seen in various muscle catabolic states including burn injury (BI), sepsis, cancer cachexia, immobilization, and denervation (1) (2) (3) (4) (5) . Burn injury is a paradigm of critical illness-induced catabolic state. In severely burned patients, muscles distant from burned site are often affected because of systemic inflammatory responses and associated metabolic derangements (6) . The muscle mass loss and consequent decreased tension-generating capacity (muscle weakness) lead s to hypoventilation with dependence on mechanical ventilator. The increased dependence on ventilators leads to ventilatorassociated pneumonia and thromboembolic complications, and/ or nosocomial sepsis, worsened prognosis, and even death. The muscle weakness also prolongs hospitalization and after-hospital rehabilitation.
Skeletal muscle protein content is maintained by a dynamic balance between protein synthesis and degradation (7) . Muscle protein degradation is characterized by increased expression of the muscle-specific ubiquitin ligases, ''atrogenes,'' namely, MuRF1 and atrogin-1, which cause muscle proteolysis. Disease-induced increased glucocorticoids, oxidative stress, dysfunction of anabolic (insulin/insulin-like growth factor-I) signals, and cytokines are known effectors of atrogene upregulation, mediated by multiple upstream signal cascades with cross-talk between these cascades (1, (7) (8) (9) . For example, forkhead box O transcriptional factors (FOXOs), including FOXO1, are well-known regulators of muscle ubiquitin ligases (1) . We previously documented that activation of Akt, a negative regulator of FOXO1, is impaired by BI (10) . Burn injury also induces activation of macrophages with release of inflammatory cytokines that lead to systemic inflammatory responses mediated via multiple downstream signaling pathways (6) . Inflammatory cytokines such as tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), and other ligands lead to activation of the canonical nuclear factor-kappa B (NFkB) pathway. Nuclear translocation of activated NF-kB in turn results in transcription of its target genes associated with acute stress responses, inflammation, and muscle atrophy (11) . In addition, the Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway are other recognized alternative pathways of inflammatory responses. Specifically, STAT3, one of seven STAT family members activated by interleukin-6 (IL-6), is associated with muscle atrophy (5, 12, 13) . Thus, suppression of systemic inflammatory signal pathways has been suggested as an important strategy against inflammation-related muscle mass loss. However, recently, clinical trials with use of specific TNF-a antibody or IL-6 inhibitor conducted in patients with cancer proved ineffective in mitigating cancer-related MW or cachectic condition (14, 15) . These results indicate that inhibition of single cytokine will show limited effect, suggesting that multiple inflammatory cytokines are involved in muscle proteolysis during systemic catabolic states.
During the past decade, it has been documented that stimulation of vagus nerve can mediate anti-inflammatory effects. For example, Wang et al. discovered that stimulation of the a7 acetylcholine receptors (a7AChRs) constitutively expressed in macrophages suppressed lipopolysaccharide (LPS)-induced TNF production (16) . Inflammatory leukocytes including macrophages are known to infiltrate muscle tissue in MW conditions of systemic inflammatory origin or even in simple disuse atrophy in the absence of systemic inflammation (17, 18) . Although the pluripotent pathways of anti-inflammatory actions of a7AChRs remain to be established, stimulation of a7AChRs mediates some of their critical anti-inflammatory signals by inhibiting two important signaling proteins, namely, NF-kB and IL-6/STAT3; the downstream effects of these two proteins cause muscle proteolysis (19) (20) (21) (22) (23) . Whether the cholinergic anti-inflammatory actions mediated via a7AChRs can modulate the augmented proteolysis observed in inflammatory catabolic condition through suppression of activated NF-kB and IL-6/STAT3 is unknown. Using a wellestablished specific a7AChR agonist, GTS-21 (23) (24) (25) (26) , the current study tested the hypothesis that the stimulation of a7AChRs with GTS-21 attenuates inflammation-induced distant MW of BI.
MATERIALS AND METHODS

Materials
GTS-21 was kindly provided by Dr. William R. Kem (University of Florida, Gainesville, Fla). Wild-type (WT) and a7AChR knockout (Chrna7 À/À ) mice on C57BL6/J background were purchased from The Jackson Laboratory (Bar Harbor, Maine). RNeasy Plus Universal Kit was from Qiagen (Germantown, Md). High Capacity RNA-to-cDNA Kit, Platinum SYBR Green qPCR SuperMix-UDG, ViiA7 real-time polymerase chain reaction (RT-PCR) system, enzyme-linked immunosorbent assay (ELISA) kit for Mouse IL-6, Pierce 660 nm Protein Assay kit, NuPAGE LDS Sample Buffer, and NuPAGE 4% to 12% Bis-Tris Gel were from Thermo Fisher Life Technologies (Grand Island, NY). Primary antibodies against FOXO1, p-Stat3-Tyr705, p-NF-kB p65-Ser536, and NF-kB p65 were obtained from Cell Signaling Technologies (Danvers, Mass); p-Stat3-Ser727, Stat3, MuRF1, and atrogin-1 were from Santa Cruz Biotechnology (Santa Cruz, Calif); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Trevigen (Gaithersburg, Md). Horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) antibody was from EMD Millipore (Danvers, Mass). Methyllycaconitine (MLA) and Protease Inhibitor Cocktail were obtained from Sigma (St. Louis, Mo). Chemiluminescent detection kit was from Denville Scientific Inc (Metuchen, NJ).
Burn mice model
The study protocol was approved by the Institutional Animal Care Committee at Massachusetts General Hospital (protocol #2013N000193). Adult male C57BL6/J mice of 22 g to 27 g body weight were housed individually for acclimation with free access to food and water for 5 to 7 days prior to burn or sham injury. Prior to each perturbation, the mice received 0.1 mg/kg of buprenorphine subcutaneously as analgesia and 50 mg/kg of pentobarbital administered intraperitoneally as the anesthetic. A 30% total body surface area full-thickness BI was produced under anesthesia by immersing the abdomen for 6 s and both sides of flank for 4 s in 808C water as described previously (27) . Sham-burned mice were immersed in lukewarm water after anesthesia. As fluid resuscitation, 1 mL of normal saline was injected immediately after burn or sham burn procedure regardless of the treatment. Burned mice were permitted to consume food ad libitum and sham-burned mice were pair fed.
Experimental design
The mice received intraperitoneal injection of 10 mg/kg of GTS-21 or equal volume of vehicle (normal saline) 1 h after burn or sham burn procedure and every 12 h thereafter until the termination of experiment. Based on the drug regimen, the mice were divided into four groups: sham-vehicle, sham-GTS, burn-vehicle, and burn-GTS. The same protocol was applied for all of the following experiment. The dose of GTS-21 was based on previous studies in rodents and our own preliminary studies. To examine systemic effects of BI or sham procedure, the body weight changes were noted, and the tibialis anterior (TA) muscle, a site distant from burned area, was harvested for assessment of muscle mass and biochemical changes. The TA was harvested because the effect of BI has been previously noted more in fasttwitch, glycolytic muscle such as TA compared with that seen on slow-twitch, oxidative muscle such as soleus, where the muscle loss was limited (28) .
Four sets of analyses were performed: in a first set of experiments, cytokine mRNA expression in skeletal muscle and IL-6 protein levels in serum were assessed 6 h after BI. According to previous studies with burns and LPS-induced septic model, cytokine levels are elevated only in the very early phase from 4 to 12 h after the perturbation (29, 30) . Therefore, we chose time point of 6 h after BI to assess cytokine levels. In a second set of experiment, molecular signals of inflammatory and proteolytic pathways were examined at postburn day 1 (PBD1). Our previous work documented that proteolytic and inflammatory signals begin to change significantly at day 1 and peak at day 2 after burn (31) . Meanwhile, our preliminary study also indicated that atrogene expression was significantly elevated at PBD1 and returned to basal levels at postburn day 3 (PBD3; Supplemental Fig. 1 , http://links.lww.com/SHK/A456). Therefore, we focused on examining muscle signaling changes at PBD1 in the second experiment. In a third experiment, body weight and muscle mass change were assessed at PBD3. In contrast to molecular signal changes, based on previous studies, muscle mass loss is most significantly observed at or after 2 days compared with that in control. This is a consequence of cumulative effects of daily negative net protein balance (9) . Thus, in this study, body weight and muscle mass changes were observed at day 3.
For the first experiment where cytokine levels were measured, the mice were anesthetized by 50 mg/kg of pentobarbital and cardiac puncture was performed to obtain blood samples, followed by collection of TA muscle samples (N ¼ 6 for sham-vehicle group, 4 for sham-GTS group, 10 for burn-vehicle group, 11 for burn-GTS group). Blood samples were centrifuged at 3000 Â g for 10 min at 48C, and the supernatant (serum) was stored at À808C for subsequent analyses. Tibialis anterior samples were immediately frozen in liquid nitrogen and stored at À808C for analyses of mRNA expression of cytokines later.
In the second experiment, TA samples were harvested at PBD1 in the same manner as the first experiment to examine molecular signals of inflammatory and proteolytic pathways. The number of mice in each group for the second experiment was as follows: N ¼ 8 for sham-vehicle group, 4 for sham-GTS group, 11 for burn-vehicle group, and 12 for burn-GTS group.
The third experiment consisted of measurement of body weight and muscle mass weight loss at PBD3. Burn injury or sham BI was produced in the same manner and treated daily for 3 days with GTS-21 or saline. After measurement of body weights, TA muscle samples were harvested at PBD3 to examine muscle mass changes (N ¼ 4 for sham-vehicle group, 4 for sham-GTS group, 8 for burn-vehicle group, 7 for burn-GTS group). Tibialis anterior muscle weights were normalized to initial (preburn) body weight as the body weight on day of harvest can be inaccurate because the BI-induced organomegaly can artifactually increase total body weight (6, 32) .
In the fourth experiment, specificity of GTS-21 for a7AChRs was assessed by using MLA, an antagonist for a7AChR, or by the use of a7AChR knockout (Chrna7 À/À ) mice on C57BL6/J background (a7KO mice). A new set of burned mice were treated with or without 3 mg/kg of MLA administered intraperitoneally 30 min before GTS-21 treatment. The dose of MLA was based on a previous study. Tibialis anterior muscle was harvested 6 h after BI and cytokine mRNA expression was measured in the same manner as the first experiment (N ¼ 8 for burn-GTS group, 7 for burn-GTS-MLA group). In the second part of the fourth experiment, burned or sham-burned a7KO mice with or without 10 mg/kg of GTS-21 treatment served to test the specificity of GTS-21 actions via a7AChRs. Measurement of TA muscle mass at PBD3 was used as the marker for the physiological effects of GTS-21. The number of animals used for this component of the experiment was as follows: N ¼ 3 for sham-vehicle group, 4 for burn-vehicle group, and 4 for burn-GTS group. The absence of Chrna7 mRNA in a7KO mice was confirmed by RT-PCR.
Real-time polymerase chain reaction
Total RNA from TA was purified by using RNeasy Plus Universal Kit and purity was confirmed using the NanoDrop ND-1000 Spectrophotometer. The first-strand cDNA was synthesized from 1 mg of total RNA using High Capacity RNA-to-cDNA Kit. Real-time polymerase chain reaction reactions were performed with ViiA7 RT-PCR system by using Platinum SYBR Green qPCR SuperMix-UDG with the following amplification parameters: 508C for 2 min and 958C for 2 min, followed by 40 cycles of 958C for 15 s and 608C for 30 s. Primers used in this study are shown in Table 1 . The mRNA levels were normalized to GAPDH levels and were expressed as arbitrary units.
Enzyme-linked immunosorbent assay
Serum IL-6 levels were determined at 6 h after BI or sham BI by using Mouse IL-6 ELISA Kit according to the manufacturer's instructions. Briefly, appropriately diluted serum samples were applied to ELISA plate along with IL-6 standards. After binding of the peroxidase-conjugated antibody, the bound quantity was measured by the reaction of chromogenic substrate at 450 nm.
Immunoblotting
Muscle samples were homogenized as described previously (2) . Briefly, TA samples were homogenized in ice-cold homogenization buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 2% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 mM sodium fluoride, 2 mM sodium vanadate, 10 mM sodium pyrophosphate, 1 mM dithiothreitol, Protease Inhibitor Cocktail). Protein concentration of the total homogenate after centrifugation at 800 Â g for 10 min was assessed and the homogenate was boiled with NuPAGE LDS Sample Buffer. Equal amounts of total protein were loaded onto NuPAGE 4% to 12% Bis-Tris Gel, electrophoresed, and transferred to nitrocellulose membranes. The membranes were blocked and incubated overnight at 48C with antibodies against FOXO1, p-Stat3-Ser727, p-Stat3-Tyr705, Stat3, p-NF-kB p65-Ser536, NF-kB p65, MuRF1, atrogin-1, and GAPDH followed by incubation with horseradish peroxidase-conjugated antirabbit IgG antibody for 1 h at room temperature. Immunoreactive proteins were visualized by using a chemiluminescent detection kit and the detected bands were quantified by NIH ImageJ software and normalized to those of GAPDH.
Statistics
Results are reported as means AE SEM. Initially, using KolmogorovSmirnov test, the data were tested for normality. For all data that were normally distributed, comparison among groups was performed by one-way analysis of variance followed by Tukey post hoc test (Figs. 2-4 ). When the data were not normally distributed (nonparametric), the Kruskal-Wallis test was used followed by two-tailed Mann-Whitney-Wilcoxon test for two independent samples (Fig. 1) . Comparison between two groups was performed by Welch t test (Fig. 5 ). Data were analyzed using GraphPad Prism version 6.07 and R version 3.3.0. A value of P 0.05 was considered statistically significant.
RESULTS
BI-induced inflammatory responses are reduced by GTS-21 treatment
In the first and second experiments, we examined whether BI activates inflammatory signals in the skeletal muscle distant from burned site. Tibialis anterior muscle samples were collected at 6 h postburn for analyses of cytokine (IL-1b, IL-6, and interleukin-10 [IL-10]) mRNA expression by RT-PCR (Fig. 1) . One of the downstream signaling proteins of IL-6 is inflammatory protein, STAT3, which activates many genes including C-X-C motif chemokine ligand 2 (CXCL2) (aka, STAT3 target gene). The downstream effects of cytokine expression on STAT3 and NF-kB were assessed by immunoblotting at PBD1.
The mRNA levels of proinflammatory IL-6, IL-1b, and CXCL2 in BI group compared with those in sham-burn group were upregulated to 56.7-fold, 3.1-fold, and 20.0-fold, respectively. GTS-21 treatment significantly ameliorated IL-6, IL-1b, and CXCL2 mRNA expression from 56.7-fold to 19.7-fold, 3.1-fold to 1.5-fold, and 20.0-fold to 4.3-fold, respectively (P ¼ 0.01, 0.05, and <0.01; Fig. 1, A-C) . Meanwhile, mRNA level of anti-inflammatory IL-10 also presented significant upregulation in BI. This increase was ameliorated by GTS-21 treatment though still significant higher level compared with sham-vehicle group (burn-vehicle group vs. burn-GTS group ¼ 11.2-fold vs. 6.5-fold compared with sham-vehicle group, P < 0.01 for sham-vehicle group vs. burn-vehicle group, P ¼ 0.01 for burn-vehicle group vs. burn-GTS group, and P < 0.01 for sham-vehicle group vs. burn-GTS group; Fig. 1D ). Serum IL-6 protein levels were also markedly increased in BI compared with sham-burn (Fig. 2) .
Increased muscle proteolytic signals of burn are ameliorated by GTS-21
Although previous studies have reported increased expression of muscle-specific ubiquitin ligases (MuRF1 and atrogin-1) in rats with BI (9), this study in mice examined the effect of GTS-21 on these atrogenes in the distant tibialis muscle at PBD1. The mRNA expression of MuRF1 in BI group increased 3.0-fold compared with that in sham-burn group and this increase was prevented by GTS-21 treatment (from 3.0-fold to 1.6-fold; Fig. 3A) . Consistent with mRNA levels, the protein expression of MuRF1 increased after BI and was reversed by GTS-21 treatment (Fig. 3D) . Meanwhile, the mRNA expression of atrogein-1 in FIG. 1 . Cytokine mRNA expressions in burned mice and their amelioration by GTS-21 treatment. Tibialis anterior muscles and serum samples were harvested at 6 h after body trunk burn injury with or without 10 mg/kg of GTS-21 or saline treatment b.i.d. Quantitative RT-PCR was performed on the total RNA purified from the harvested muscles. Relative quantification of proinflammatory IL-6 (A), IL-1b (B), CXCL2 (C), and anti-inflammatory IL-10 (D) transcripts normalized to that of GAPDH is shown as bar graph with the standard error. The levels of IL-6, IL-1b, and CXCL2 transcripts were increased in burn injury to 56.7-fold, 3.1-fold, and 20.0-fold, respectively. GTS-21 treatment significantly ameliorated these cytokine levels from 56.7-fold to 19.7-fold, 3.1-fold to 1.5-fold, and 20.0-fold to 4.3-fold, respectively. The level of IL-10 was also increased in burn and reduced by GTS-21 (burn-vehicle group vs. burn-GTS group ¼ 11.2-fold vs. 6.5-fold). Serum IL-6 levels (E) were also significantly increased in BI compared with those in sham-burn group and significantly ameliorated by GTS-21 treatment (sham-vehicle group vs. burn-vehicle group vs. burn-GTS group ¼ 24.5 AE 7.9 pg/mL vs. 520.3 AE 21.2 pg/mL vs. 414.0 AE 36.0 pg/mL). ( * ) P 0.05 versus shamvehicle group; (#) P 0.05 versus burn-vehicle group, N ¼ 6 for sham-vehicle group, 4 for sham-GTS group, 10 for burn-vehicle group, and 11 for burn-GTS group. The fold increase was calculated by comparing with the value of sham-vehicle group. CXCL2 indicates C-X-C motif chemokine ligand 2; IL-1b, interleukin-1b; IL-6, interleukin-6; IL-10, interleukin-10; RT-PCR, real-time polymerase chain reaction.
BI group increased 2.0-fold compared with that in sham-burn group and GTS-21 treatment ameliorated the increase (from 2.0-fold to 1.5-fold; Fig. 3B ). Intriguingly, neither BI nor GTS-21 treatment significantly altered atrogin-1 protein levels (Fig. 3E) .
GTS-21 treatment ameliorated induction of FOXO1 after BI
It has been reported that IL-6/STAT3 pathway is an upstream signaling partner involved in regulation of MuRF1 and atrogin-1. However, these same genes are also regulated by an alternative pathway, namely, FOXO1. We, therefore, next examined whether BI and GTS-21 treatment affect FOXO1 expression. Forkhead box O transcriptional factor 1 mRNA expression in BI mice was increased 4.0-fold compared with that in shamburn mice. GTS-21 treatment reduced the expression (from 4.0-fold to 1.8-fold; Fig. 3C ). Consistent with the mRNA data, BI significantly increased FOXO1 protein expression and the increase was ameliorated by GTS-21 (from 4.1-fold to 2.6-fold; Fig. 3F ).
Total body weight and distant skeletal muscle mass loss of BI are mitigated by GTS-21
The third experiment examined the body weight and muscle mass changes induced by BI and GTS-21 therapy. The total body weight decreased 5.6% in burn-vehicle group compared with that in sham-vehicle group at day 3 after BI (P ¼ 0.02). GTS-21 treatment after BI mitigated the weight loss and maintained the body weight similar to that of sham BI (P ¼ 0.32, sham-vehicle group vs. burn-GTS group; Fig. 4A ). Furthermore, TA muscle weight in burn-GTS group improved significantly compared with that in burn-vehicle group (1.76 mg/g body weight vs. 1.59 mg/g body weight, P ¼ 0.02; Fig. 4B ). In other words, BI decreased TA muscle mass 13.2% at day 3 and this loss was significantly decreased to 4.0% by GTS-21.
MLA treatment of WT or genetic deletion of a7KO mice abrogates the GTS-21 effects
The previous experiments presented the beneficial effects of GTS-21 on skeletal muscle mass loss as well as abrogation of the inflammatory and proteolytic signaling pathways after BI. The following study examined whether GTS-21 specifically exerts its effect through a7AChRs. A new set of BI mice were treated with GTS-21 alone or in combination with MLA, a specific antagonist of a7AChRs. The addition of MLA to GTS-21-treated mice increased mRNA expression of IL-6 2.9-fold (P < 0.01) and CXCL2 4.4-fold (P < 0.01) (Fig. 5, A and C) . IL-1b mRNA expression presented similar trend but was not statistically significantly different (1.4-fold increase, P ¼ 0.20; Fig. 5B ). Consistent with the absence of GTS-21 effects on burn-injured receiving a7AChR antagonist, MLA, GTS-21 treatment did not improve TA muscle mass loss in a7KO mice (burn-vehicle group vs. burn-GTS group ¼ 1.66 mg/g body weight vs. 1.62 mg/g body weight, P ¼ 0.81; Fig. 5D ).
DISCUSSION
The current study documents for the first time that stimulation of a7AChRs by specific agonist, GTS-21, ameliorated the following: BI-induced mRNA expression of inflammatory cytokines in skeletal muscle and serum IL-6 protein expression; increased phosphorylation (activation) of NF-kB and STAT3 signals; increased expression of proteolytic signals (MuRF1 and FOXO1); and BI-induced body weight loss and skeletal muscle mass loss in WT mice. Importantly, as opposed to beneficial responses to GTS-21 treatment in BI WT mice, the treatment of BI in a7KO mice with GTS-21 or concomitant treatment of WT mice with GTS-21 and MLA failed to exert the protective effect on muscle mass loss or cytokine expression. These data indicate that the beneficial effects of GTS-21 were mediated specifically via a7AChRs.
Most acquired MW conditions are associated with some form of systemic or local inflammation (4, 6, 8, 11, 12) . The   FIG. 2 . Phosphorylation of STAT3 induced in skeletal muscle with burn injury and its attenuation by GTS-21 treatment. Phosphorylation status of STAT3 at tyrosine 705 (A) and serine 727 (B) was analyzed by immunoblotting and quantified after normalization to total STAT3, and phosphorylated NF-kB by normalized to total NF-kB (C) at postburn day 1. Phosphorylated STAT3 at tyrosine 705, serine 727, and phosphorylated NF-kB were increased in burn injury to 8.1-fold, 2.2-fold, and 1.8-fold, respectively, compared with that in sham-burn group. These increases were significantly ameliorated by GTS-21 treatment (from 8.1-fold to 4.1-fold, 2.2-fold to 1.4-fold, and 1.8-fold to 1.0-fold, respectively). ( * ) P 0.05 versus sham-vehicle group; (#) P 0.05 versus burn-vehicle group, N ¼ 8 for sham-vehicle group, 4 for sham-GTS group, 11 for burn-vehicle group, and 12 for burn-GTS group. The fold increase was calculated by comparing with the value of sham-vehicle group. NF-kB indicates nuclear factor-kappa B; STAT3, signal transducer and activator of transcription 3.
infiltration of circulating leukocytes into muscle during MW is also now well established (17) . Even in simple disuse atrophy, despite the absence of systemic inflammatory response, muscle inflammation and infiltration of macrophages have been evidenced (18) . There is also a priori evidence that there is de novo expression of a7AChRs in muscle during muscle cachexia even in the absence of systemic inflammation. The upregulation of a7AChRs has been observed in skeletal muscle under certain catabolic conditions including simple disuse (3) and motor nerve denervation (33) . In view of the fact that these leukocytes and muscle express a7AChRs, we exploited the anti-inflammatory properties of a7AChRs to decrease inflammation in skeletal muscle. This was achieved by the use of a specific a7AChR agonist GTS-21. Our studies provide evidence that stimulation of a7AChRs does indeed decrease systemic inflammation evidenced by decrease of IL-6 protein levels in association with maintenance of body weight and attenuation of muscle mass loss. Our studies, however, identified neither if the effects of GTS-21 were more prominent systemically or locally nor if the effects of GTS-21 were predominantly on muscle or leukocyte a7AChRs.
GTS-21 suppressed muscle inflammatory responses
The current study demonstrated the beneficial effects of GTS-21 on inflammatory responses after BI. GTS-21 treatment suppressed proinflammatory cytokine mRNA expression including IL-6, IL-1b, and CXCL2 in skeletal muscle. IL-10, an anti-inflammatory cytokine, was also elevated after BI at this time point of the current study, which most likely means simultaneously increased synthesis of anti-inflammatory markers counteracting the proinflammatory cytokines as similarly observed in a previous study (24) . Unexpectedly, IL-10 level was reduced by GTS-21 but still significantly higher than sham-vehicle group. Although the precise reason about this result is unclear, this observation might be because of secondary effect through suppression of systemic and local inflammation. The effect of a7AChRs on anti-inflammatory cytokines is controversial (24, 26, 34) . Further study is required to elucidate the involvement of a7AChRs in anti-inflammatory cytokine release and their effects on muscle mass loss and/ or recovery.
Having demonstrated the beneficial effects of GTS-21 on inflammatory responses after BI, we next examined the biochemical and anti-inflammatory effects of GTS-21. Systemic administration of GTS-21 suppressed inflammatory responses in muscle as indicated in change of inflammatory cytokine (22) . Thus, whether stimulation of a7AChRs induces or reduces STAT3 activation depends on target organs/tissues and/or experimental condition. However, both reports are in agreement that stimulation of a7AChRs has anti-inflammatory effects eventually suppressing NF-kB activation and/or inflammatory cytokines. Thus, our studies are consistent with these studies that agonistic stimulation of a7AChRs leads to NF-kB inhibition in vivo.
Although phosphorylation of STAT3 on tyrosine 705 is the canonical JAK target site, serine 727 phosphorylation site was also phosphorylated by BI (Fig. 2) . The significance of phosphorylation of serine 727 following BI in terms of inflammation is unclear. The latter observation is possibly due to multiple and complex inflammatory and immune responses induced by severe BI. Importantly, however, both tyrosine 705 and serine 727 phosphorylation of STAT3 were significantly reduced by GTS-21 treatment. Phosphorylation of STAT3 on serine 727 is mediated by signals including protein kinase C, Jun N-terminal kinase, extracellular signal-regulated kinase, and the mitogenactivated protein kinase p38 (35) . Thus, GTS-21 may affect these signaling molecules in addition to canonical NF-kB and IL-6/STAT3 pathways. These results indicate that stimulation of a7AChRs by GTS-21 has pluripotent beneficial effects.
GTS-21 suppressed BI-induced upregulated proteolytic signals
Several in vitro and in vivo studies have already documented the important roles of cytokines in muscle protein loss (1, 13) . These studies suggest that increased expression of inflammatory cytokines, at least in part, may contribute MW in catabolic conditions. Muscle wasting of critical illness of BI results from an imbalance of the anabolic (synthetic) and catabolic (proteolytic) machinery (1) . In BI there is evidence for increased protein degradation (9) . In rodent studies, although Akt signaling is impaired in BI, the phosphorylation of p70S6, one of the major signals for protein synthesis, was increased compared with that in controls, suggesting higher than normal protein synthesis (10) . Regardless of increased protein synthesis, MW persists in BI, suggesting that protein degradation is greater than synthesis. Our studies demonstrate that elevated atrogene expression is mitigated by GTS-21 in association with maintenance of muscle mass after BI. This suggests that the protein degradation has been effectively inhibited by GTS-21. The effect of GTS-21 on synthesis is unclear and subject to future studies.
Previous studies identified FOXO1, NF-kB, and STAT3 as effectors of MW (1, 4, 5, 7, (11) (12) (13) ). In the current study NF-kB, STAT3, and FOXO1 activation was reduced by GTS-21 treatment in BI animals. Both mRNA and protein expression of MuRF1, a major ubiquitin ligase related to muscle atrophy, were reduced by GTS-21 treatment. Although mRNA expression of atrogin-1 presented the same trend as MuRF1, the level of atrogin-1 protein expression was not significantly altered by BI or GTS-21. This discrepancy between protein and mRNA has been previously observed in ventilator-induced MW (12) , possibly due to the difference in the kinetics between protein and mRNA regulation.
The current study also provides evidence that stimulation of a7AChRs suppresses BI-induced increased expression of FOXO1 in skeletal muscle. In this study, total FOXO1 mRNA and protein expression were examined because it had been reported that FOXO1 activation is caused by increased level of total FOXO1 protein in catabolic conditions such as starvation (36) or sepsis (37) , although reduction of phosphorylated FOXO1 is also an important mechanism of activation of FOXO1. Although the mechanisms that regulate FOXO1 signal were not investigated in this study, Wang et al. reported that stimulation of a7AChRs ameliorates obesity-induced insulin resistance by enhancing insulin signals such as Akt that also works as a regulator of FOXO1 signal (38) . It is conceivable that GTS-21 treatment affects Akt activity leading to suppression of FOXO1 signal. However, it does not exclude the possibility that GTS-21 reduces FOXO1 expression secondarily through suppression of systemic and local inflammation. Further studies are necessary to elucidate a link between a7AChRs and the FOXO1 pathway. Taken together, the current results suggest that stimulation of a7AChRs by GTS-21 treatment regulates not only inflammatory responses but also proteolytic signals such as MuRF1 and FOXO1 signal.
GTS-21 retarded BI-induced body weight and muscle mass loss
Next the physiological consequences of attenuation of BIinduced inflammatory responses and augmented proteolytic signals by GTS-21 were examined by observation of body weight and muscle mass changes since this is the most important goal from a clinical perspective. Our study documents that the increased expression of muscle-specific ubiquitin ligases by BI caused skeletal muscle mass loss at PBD3 (Fig. 4) . Stimulation of a7AChRs by GTS-21 treatment significantly ameliorated not only the TA muscle mass loss but also whole body weight loss induced by BI.
The beneficial effects of GTS-21 were blocked by specific inhibition of a7AChRs
Finally, the specificity of GTS-21 for a7AChRs was examined. Pharmacological inhibition of a7AChRs by MLA treatment blocked the effect of GTS-21, which reduced proinflammatory cytokine mRNA expression after BI. Similarly, GTS-21 treatment did not prevent BI-induced muscle mass loss in a7KO mice. These observations confirm the specificity of GTS-21 actions being exerted via stimulation of a7AChRs.
In conclusion, the current study demonstrates that pharmacotherapeutic stimulation of a7AChRs by a specific agonist, GTS-21, ameliorates BI-induced induction of proteolytic signals including MuRF1 and FOXO1, as well as inflammatory responses mediated by NF-kB and IL-6/STAT3 pathways in
